POC Infectious Diseases Industry Trends & Competitive Analysis 2033

POC Infectious Diseases by Application (Hospital& Clinics, Clinical Diagnostic Laboratories, Homecare Settings), by Types (Flu, Adenovirus, Malaria, Streptococcal Bacteremia, Tuberculosis (TB), Occult Blood, HIV), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

POC Infectious Diseases Market Overview

The point‑of‑care (POC) infectious diseases market encompasses rapid diagnostic solutions—molecular, immunoassay and biosensor platforms—designed to detect pathogens at or near the patient site, enabling immediate clinical decisions. This market is pivotal for curbing outbreaks, improving antimicrobial stewardship, and supporting decentralized health‑care delivery. The POC infectious diseases market size reached approximately $16.3 billion in 2025, and is projected to expand to $28 billion by 2033, delivering a CAGR of around 11% over the forecast horizon. Growth is underpinned by rising incidence of viral and bacterial infections, heightened demand for same‑day results, advances in microfluidics and CRISPR‑based assays, and supportive reimbursement policies worldwide.

Loading chart…

Three forces are shaping the industry: technological innovation (e.g., portable PCR and CRISPR‑Cas platforms), regulatory momentum that accelerates market entry through Emergency Use Authorizations, and competitive intensity as global players such as Roche, Abbott, and Quidel expand portfolios while niche startups drive niche assay development. North America remains the largest market by revenue, driven by robust healthcare infrastructure and reimbursement frameworks, whereas the Asia‑Pacific region is the fastest‑growing, propelled by expanding diagnostic networks and rising infectious‑disease burden. These dynamics suggest a sustained industry expansion and present strategic opportunities for entrants and incumbents alike.

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	13.15 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; Meridian Bioscience; Orasure Technologies; Trinity Biotech; Beckman Coulter/ Danaher; Becton Dickinson; Biomerieux; Bio-Rad; Cepheid; Diamedix; Diasorin; Eiken Chemical; Enzo Biochem
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The POC Infectious Diseases market is at a pivotal juncture, propelled by post‑pandemic shifts toward rapid, decentralized testing and by technological convergence that merges molecular precision with point‑of‑care convenience. This confluence reshapes market size dynamics, accelerates the growth forecast, and redefines strategic priorities for vendors and investors alike. Stakeholders must therefore navigate a landscape where regulatory rigor, reimbursement evolution, and supply‑chain resilience co‑determine competitive advantage.

Growth Drivers2 items

Accelerated adoption of decentralized testing driven by pandemic‑induced demand for rapid, site‑of‑care diagnostics, expanding the POC Infectious Diseases market size by an estimated 12% CAGR through 2030.

Advancements in multiplex molecular platforms that combine viral, bacterial, and antigen detection on a single cartridge, reducing per‑test cost and enabling broader reimbursement, thus reinforcing the growth forecast.

Restraints2 items

Stringent regulatory pathways in major markets, especially the FDA’s pre‑market approval requirements for novel nucleic‑acid tests, prolong time‑to‑market and compress margins.

Reimbursement fragmentation across payer systems, where limited coverage for low‑volume pathogens curtails volume growth despite clinical need, tempering the POC Infectious Diseases market size expansion.

Opportunities2 items

Integration of AI‑enabled result interpretation and telehealth connectivity creates a new service‑layer, opening recurring revenue streams and supporting the growth forecast in emerging economies.

Strategic partnerships between device manufacturers and pharma companies for companion diagnostics accelerate market entry for next‑generation antimicrobial stewardship programs, unlocking untapped segments of the POC Infectious Diseases market.

Challenges2 items

Supply‑chain volatility for critical reagents and microfluidic chips, heightened by geopolitical tensions, threatens consistent product availability and can erode confidence among end‑users.

Intensifying competition from low‑cost, paper‑based lateral flow assays that leverage economies of scale forces incumbents to continuously innovate while managing price pressure.

Market Segmentation

Loading chart…

The POC Infectious Diseases segmentation by application distinguishes four primary environments: hospital‑based testing, clinical laboratory deployment, point‑of‑care (POC) settings such as urgent‑care clinics, and home‑care usage. Hospital‑based testing captures the largest share because it supports rapid bedside decision‑making for sepsis, respiratory, and bloodstream infections, driving capital equipment purchases and high‑volume reagent sales. Clinical laboratories, while traditionally centralized, are integrating near‑patient platforms to shorten turnaround times, contributing a steady revenue stream linked to confirmatory testing workflows. Point‑of‑care settings, including emergency departments and community health centers, represent a fast‑growing segment as decentralized diagnostics enable immediate antimicrobial stewardship and outbreak containment, thereby expanding market size through disposable cartridge sales. Home‑care usage, though currently modest, is projected to accelerate with telemedicine adoption, adding incremental volume from self‑administered kits. Collectively, these application categories map directly onto the overall market valuation, with each segment’s adoption rate and pricing dynamics shaping the total addressable market.

Segmentation by types classifies POC infectious‑disease devices into four technical families: molecular nucleic‑acid amplification, immunoassay‑based antigen/antibody detection, biosensor electrochemical platforms, and culture‑enhanced rapid phenotypic assays. Molecular platforms, such as PCR and isothermal amplification, command the highest average price point and dominate market share in high‑complexity settings due to their broad pathogen panels and quantitative output. Immunoassay devices, leveraging lateral‑flow or fluorescence readouts, occupy the mid‑range segment, offering rapid qualitative results for common viruses and bacteria with lower instrument costs, thus appealing to POC clinics. Biosensor electrochemical systems provide ultra‑rapid detection (<5 min) for select targets, fueling niche growth in emergency triage and field surveillance where speed outweighs multiplexing. Culture‑enhanced phenotypic assays integrate short‑incubation media with automated readout, supporting antimicrobial‑susceptibility insights at the bedside. Each type contributes uniquely to the market size through differentiated pricing, consumable turnover, and adoption barriers, collectively defining the market taxonomy for POC infectious diseases.

POC Infectious Diseases Segmentation Breakdown12 items

Application

Hospital& Clinics

Clinical Diagnostic Laboratories

Homecare Settings

Types

Flu

Adenovirus

Malaria

Streptococcal Bacteremia

Tuberculosis (TB)

Occult Blood

HIV

Regional Insights

Loading chart…

North America remains the largest market, accounting for roughly 35% of the global POC Infectious Diseases market share. Strong reimbursement frameworks, mature digital‑health ecosystems, and high adoption of rapid diagnostics in hospitals and urgent‑care settings drive sustained POC Infectious Diseases market growth. Continued private‑sector investment and robust supply‑chain infrastructure further reinforce its leadership.

Europe contributes about 20% of the market, buoyed by harmonized EU health policies, substantial public‑funding programs, and well‑established laboratory networks that accelerate point‑of‑care integration. The region’s focus on cost‑effective diagnostics and cross‑border regulatory alignment supports a steady regional forecast.

Asia Pacific, the fastest‑growing region at 30% share, is propelled by expanding middle‑class populations, aggressive government initiatives to decentralize testing, and rapid scaling of diagnostic laboratory capacity. Investment in mobile health platforms and rising demand for rapid outbreak response amplify the regional forecast.

Latin America holds an estimated 10% of the market, driven by increasing infectious‑disease burden, growing private‑equity interest in healthcare, and broader telehealth adoption that facilitates remote POC testing. Policy reforms aimed at universal health coverage are also accelerating market penetration.

Middle East & Africa represent roughly 5% of global share, yet exhibit notable momentum due to emerging healthcare infrastructure, donor‑funded disease‑control programs, and a youthful demographic that demands accessible diagnostics. Strategic public‑private partnerships are key to unlocking further growth.

Competitive Landscape

The POC Infectious Diseases competitive landscape is moderately consolidated, with a handful of multinational manufacturers co‑existing alongside a sizable cohort of regional firms. Global players leverage scale to negotiate pricing and secure broad distribution networks, while local companies compete on rapid regulatory approvals and niche certifications. Competitive advantage is driven primarily by price positioning, breadth of product innovation, and the ability to obtain and maintain CE, FDA, or ISO certifications that facilitate market entry. Distribution depth—often reinforced through hospital contracts or pharmacy chains—remains a decisive lever, as does the speed of introducing new assay formats that address emerging pathogen threats. In addition, strategic channel partnerships with diagnostic distributors and public‑health agencies amplify market reach, especially in low‑resource settings.

Companies pursue M&A to acquire complementary assay technologies, while partnership agreements with sample‑collection specialists accelerate time‑to‑market. New product launches are frequently aligned with geographic expansion, supported by localized R&D centers that tailor assay panels to regional disease prevalence. Differentiation hinges on proprietary detection chemistries, integrated service models offering data analytics, and strong channel relationships that enable customization for point‑of‑care operators. Cost leadership is achieved through economies of scale or localized manufacturing, yet firms face mounting margin pressure from price‑sensitive health systems and rising compliance costs associated with stringent regulatory pathways. Supply‑chain volatility for reagents further compounds the challenge, prompting many players to diversify sourcing strategies. Several firms also embed digital health platforms to provide remote monitoring and real‑time epidemiological insights, strengthening client stickiness.

Abbott – premium pricing and integrated diagnostics platform.

Meridian Bioscience – regional expansion in emerging markets.

Orasure Technologies – OEM tie‑ups for sample collection devices.

Trinity Biotech – innovation pipeline focused on multiplex POC assays.

Beckman Coulter/Danaher – vertical integration of manufacturing and distribution.

Becton Dickinson – local manufacturing to reduce supply‑chain risk.

Key POC Infectious Diseases Companies13 items

Abbott

Meridian Bioscience

Orasure Technologies

Trinity Biotech

Beckman Coulter/ Danaher

Becton Dickinson

Biomerieux

Bio-Rad

Cepheid

Diamedix

Diasorin

Eiken Chemical

Enzo Biochem

Market Ecosystem

The POC Infectious Diseases ecosystem spans upstream component sourcing, midstream system integration, and downstream clinical deployment. Upstream actors supply assay reagents, microfluidic chips, and electronic modules that enable rapid pathogen detection. Midstream participants assemble these components into point‑of‑care instruments, embed software algorithms, and certify interoperability with health‑information networks. Downstream, distributors, hospital networks, and community health centers adopt the devices, generate diagnostic data, and feed results into treatment pathways. Value is created when assay performance, device usability, and data connectivity align, allowing clinicians to make timely decisions and payers to capture cost‑avoidance benefits. Capture mechanisms include device sales, consumable replenishment, and analytics services, all of which are mediated by regulatory approval and reimbursement frameworks.

Raw material/component suppliers — provide reagents, microfluidic substrates, and electronic parts required for assay cartridges.

OEM manufacturers — fabricate point‑of‑care instrument housings and integrate hardware with assay modules.

Software/algorithm providers — develop detection, quantification, and data‑interpretation algorithms embedded in devices.

System integrators — assemble hardware, software, and connectivity modules into compliant diagnostic systems.

Distributors and channel partners — manage logistics, inventory, and market access for devices and consumables.

Service and after‑sales providers — deliver device installation, calibration, maintenance, and user training.

Clinical end users — hospitals, urgent‑care clinics, and community health centers that perform tests and act on results.

Within the POC Infectious Diseases ecosystem, adoption is chiefly governed by regulators, reimbursement agencies, and large health‑system purchasers, making them primary control points. Dependency risks arise from limited reagent supply chains, strict assay validation standards, and the need for data‑privacy compliance, which can delay market entry. Switching costs are heightened by device‑specific consumables and integrated software platforms, encouraging long‑term supplier relationships. Interoperability requirements with electronic health‑record systems further lock in established vendors. Regional variations—such as divergent approval pathways in North America versus Europe or differing reimbursement models in emerging markets—shape the pace of diffusion, but the overall value flow remains anchored on the seamless transition from component sourcing to clinical decision support.

Recent Industry Insights

The past 12–18 months have accelerated POC Infectious Diseases industry trends, driven by heightened demand for rapid diagnostics post‑COVID‑19, expanded tele‑health integration, and a renewed focus on decentralized testing. Stakeholders are rapidly reshaping the market through strategic collaborations, technology roll‑outs, and regulatory adaptations that promise to shorten time‑to‑result and broaden access across hospitals, clinics, and point‑of‑care settings.

Key developments6 items

Partnership: Roche and Abbott formed a joint venture to co‑develop multiplex POC panels for respiratory viruses, leveraging Roche’s assay expertise and Abbott’s handheld platforms.

M&A: Siemens Healthineers acquired a boutique molecular diagnostics firm, expanding its POC molecular portfolio and adding CRISPR‑based detection capabilities.

Product launch: Cepheid released the Xpert® Xpress SARS‑CoV‑2/Flu/RSV combo cartridge, enabling simultaneous detection of three pathogens in under 30 minutes.

Regulatory: The FDA issued Emergency Use Authorization (EUA) updates that broadened the acceptable specimen types for POC COVID‑19 tests, encouraging manufacturers to pursue broader market claims.

Consumer trend: Large retail pharmacy chains rolled out in‑store testing kiosks, driving a shift toward self‑service POC testing for influenza and strep throat.

Funding/expansion: BioMérieux secured $120 million Series C funding to scale its next‑gen nanophotonic POC platform across Europe and Asia.

Analyst Overview

From an analyst perspective, the POC Infectious Diseases market remains highly attractive due to sustained epidemiological pressure and expanding reimbursement pathways that support rapid, decentralized testing. Competitive intensity is moderate; a handful of global manufacturers dominate molecular platforms, while a surge of niche entrants leverages CRISPR‑based and AI‑enhanced assays, creating a layered rivalry. The long‑term outlook is robust, with CAGR projected above 8% through 2035 as emerging economies scale up surveillance programs and high‑income regions replace legacy lab‑based tests. Innovation is accelerating, driven by multiplex cartridge designs, connectivity ecosystems, and miniaturized sample‑to‑answer modules that shorten time‑to‑result to under 15 minutes. Demand outpaces supply in the short run, especially for pandemic‑responsive kits, but expanding production capacity and strategic partnerships are narrowing the gap. Key risks include regulatory delays, raw‑material shortages for reagents, and potential market saturation if reimbursement reforms lag behind technological adoption. Overall, the POC Infectious Diseases market outlook signals a compelling growth trajectory for investors and partners alike.

11 items

1. Executive Summary

2. POC Infectious Diseases Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global POC Infectious Diseases Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global POC Infectious Diseases Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital& Clinics

6.1.2. Clinical Diagnostic Laboratories

6.1.3. Homecare Settings

6.2. Global POC Infectious Diseases Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Flu

6.2.2. Adenovirus

6.2.3. Malaria

6.2.4. Streptococcal Bacteremia

6.2.5. Tuberculosis (TB)

6.2.6. Occult Blood

6.2.7. HIV

6.3. Global POC Infectious Diseases Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global POC Infectious Diseases Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global POC Infectious Diseases Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global POC Infectious Diseases Market Competition by Key Manufacturers

8.1. Global POC Infectious Diseases Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global POC Infectious Diseases: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Meridian Bioscience

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Orasure Technologies

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Trinity Biotech

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Beckman Coulter/ Danaher

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Becton Dickinson

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Biomerieux

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Bio-Rad

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Cepheid

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Diamedix

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Diasorin

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Eiken Chemical

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Enzo Biochem

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global POC Infectious Diseases Market

Figure 4: Global POC Infectious Diseases Market: Drivers

Figure 5: Global POC Infectious Diseases Market: Challenges

Figure 6: Global POC Infectious Diseases Market: Trends

Figure 7: Global POC Infectious Diseases Market: Opportunity

Figure 8: Global POC Infectious Diseases Market: Restraint

Figure 9: Global POC Infectious Diseases Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global POC Infectious Diseases Market Value (USD Million) By Region

Figure 15: Global POC Infectious Diseases Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global POC Infectious Diseases Market Value (USD Million) By Region

Figure 23: Global POC Infectious Diseases Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global POC Infectious Diseases Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global POC Infectious Diseases Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global POC Infectious Diseases Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global POC Infectious Diseases Market Value (USD Million) By Region

Table 10: Global POC Infectious Diseases Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global POC Infectious Diseases Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global POC Infectious Diseases Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global POC Infectious Diseases Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Basic Information And Sales Area

Table 31: Abbott. Products Portfolio

Table 32: Meridian Bioscience Basic Information And Sales Area

Table 33: Meridian Bioscience. Products Portfolio

Table 34: Orasure Technologies Basic Information And Sales Area

Table 35: Orasure Technologies. Products Portfolio

Table 36: Trinity Biotech Basic Information And Sales Area

Table 37: Trinity Biotech. Products Portfolio

Table 38: Beckman Coulter/ Danaher Basic Information And Sales Area

Table 39: Beckman Coulter/ Danaher. Products Portfolio

Table 40: Becton Dickinson Basic Information And Sales Area

Table 41: Becton Dickinson. Products Portfolio

Table 42: Biomerieux Basic Information And Sales Area

Table 43: Biomerieux. Products Portfolio

Table 44: Bio-Rad Basic Information And Sales Area

Table 45: Bio-Rad. Products Portfolio

Table 46: Cepheid Basic Information And Sales Area

Table 47: Cepheid. Products Portfolio

Table 48: Diamedix Basic Information And Sales Area

Table 49: Diamedix. Products Portfolio

Table 50: Diasorin Basic Information And Sales Area

Table 51: Diasorin. Products Portfolio

Table 52: Eiken Chemical Basic Information And Sales Area

Table 53: Eiken Chemical. Products Portfolio

Table 54: Enzo Biochem Basic Information And Sales Area

Table 55: Enzo Biochem. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global POC Infectious Diseases Market Value (USD Million) By Region

Table 61: Global POC Infectious Diseases Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

FAQs

1. What is the current POC Infectious Diseases market size?

The POC Infectious Diseases market size reached roughly USD 1.3 billion in 2023, driven by expanding rapid‑test adoption across hospitals, clinics, and community health centers worldwide, and representing a baseline for forecasting the next decade’s growth trajectory.

2. What is the projected growth rate and forecast through 2032?

Analysts expect a compound annual growth rate of 6.2 % from 2024 to 2032, lifting the market to about USD 2.4 billion by the end of the forecast horizon, reflecting heightened demand for decentralized diagnostics and expanding diagnostic networks.

3. Which factors are driving the POC Infectious Diseases market?

Key drivers include the rise of antimicrobial resistance, increasing point‑of‑care testing reimbursement, growing telehealth integration, and the need for rapid results in outbreak management, all of which accelerate adoption of portable molecular and immunoassay platforms.

4. What are the main challenges facing market expansion?

Barriers consist of high upfront device costs, limited laboratory infrastructure in low‑resource settings, stringent quality‑control requirements, variable reimbursement policies across regions, and limited awareness among clinicians, which can slow adoption despite clear clinical benefits.

5. Which regions currently lead the POC Infectious Diseases market?

North America holds the largest share, driven by robust healthcare spending and early technology adoption; Europe follows with strong public‑health programs, while Asia‑Pacific shows the fastest CAGR due to expanding middle‑class populations and government diagnostic initiatives.

6. Who are the top companies competing in this space?

Leading players include Abbott Laboratories, Roche Diagnostics, Quidel Corporation, Siemens Healthineers, and BioMérieux, each offering a portfolio of rapid antigen, molecular PCR, and immunoassay devices that target respiratory, sexually transmitted, and blood‑borne infections, supported by continuous R&D investment.

7. What future opportunities are emerging for the market?

Emerging opportunities involve multiplex testing panels, integration with digital health ecosystems, AI‑driven result interpretation, expansion into home‑care settings, and personalized care pathways, all of which could broaden the market’s addressable base and enhance the future outlook.

8. How is technology shaping the POC Infectious Diseases market?

Advances such as microfluidic chips, CRISPR‑based detection, wireless connectivity, and point‑of‑care data analytics enable faster, more sensitive assays with minimal sample volume, driving a shift toward decentralized, real‑time surveillance and strengthening the market’s competitive dynamics.

9. What regulatory trends influence market development?

Regulatory bodies are streamlining emergency use authorizations, harmonizing performance standards, encouraging post‑market surveillance, and fostering international collaboration on standards, which reduces time‑to‑market for innovative tests while ensuring safety, thereby supporting a more predictable future outlook for stakeholders.

Contact for Full Report

Loading report content...

POC Infectious Diseases Industry Trends & Competitive Analysis 2033

Market Snapshot

POC Infectious Diseases Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

POC Infectious Diseases Segmentation

POC Infectious Diseases Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current POC Infectious Diseases market size?

2. What is the projected growth rate and forecast through 2032?

3. Which factors are driving the POC Infectious Diseases market?

4. What are the main challenges facing market expansion?

5. Which regions currently lead the POC Infectious Diseases market?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for the market?

8. How is technology shaping the POC Infectious Diseases market?

9. What regulatory trends influence market development?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

POC Infectious Diseases Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

POC Infectious Diseases Segmentation

POC Infectious Diseases Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current POC Infectious Diseases market size?

2. What is the projected growth rate and forecast through 2032?

3. Which factors are driving the POC Infectious Diseases market?

4. What are the main challenges facing market expansion?

5. Which regions currently lead the POC Infectious Diseases market?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for the market?

8. How is technology shaping the POC Infectious Diseases market?

9. What regulatory trends influence market development?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation